Overview
Financials
Revenue history (in k)
Filing timeliness
2 of 5 financial statements were filed late (the longest delay 90 days for 2021).
- 202516/07/2026
- 202415/07/2025
- 202314/07/2024
- 202215/07/2023
- 202113/10/2022
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Offer
- Biotechnology research
- Enzybiotic development
- Antimicrobial therapeutics
- Protein engineering
- Enzyme product development
Website technology
- Website
- WordPress
Public procurement
Enzybiotx is the contractor in 2 public sector contracts, worth USD 189.09 in total. All of them were signed with the same public buyer.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Sep 4, 2026 | Aurezyna enzyme 1.5 mg; | $94.54 | Uniwersytet Warszawski | |
| Jul 23, 2026 | Reagents for molecular biology | $94.54 | Uniwersytet Warszawski |
Authorized Representatives
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Elżbieta Monika Jagielskaage 51 | 40 | $540.25 | 38.835% |
Przemysław Michał Michalakage 41 | 20 | $270.12 | 19.4175% |
Izabela Sabałaage 60 | 40 | $540.25 | 38.835% |
Others | 3 | $40.52 | 2.9125% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Oct 25, 2022 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $23,553$23,553 | Excento sp. z o.o. |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-06-01 | 101072288 - Enzybiotx - upgrading business potential of enzybiotx | $78,837$78,837 | 1.0.11 - Horizon Europe |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| UrtesteS.A. | $701,908.59 | urteste.com | ||
| Phage Consultantssp. z o.o. | $193,130.82 | phageconsultants.com | ||
| Innervisionsp. z o.o. | $132,625.90 | innervision.pl | ||
| AI Corelabsp. z o.o. | $106,857.00 | aicorelab.com | ||
| Receptonsp. z o.o. | $50,611.05 | receptonbiotech.com | ||
| Detoxedsp. z o.o. | $11,972.37 | detoxed.pl | ||
| ArthecS.A. | $10,911.16 | arthec.eu | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| Astrofoodssp. z o.o. | $3,665.32 | astrofarms.space |
Change history
| Date | Event | |
|---|---|---|
| 2022-12-30 | Share capital increase (5,000.00 PLN → 5,150.00 PLN) | |
| 2020-09-08 | Entered in the register |
FAQ
Last updated: 2026-07-16